<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-472
Date of Submission: 2024-09-08

This report was submitted by a Pharmacist from Marshall Inc Medical Center concerning patient ANON-PX-7528. The subject is a 89-year-old female with a significant medical history including coronary artery disease, asthma, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Intramuscular route at a dosage of 46mg, initiated on 2024-07-04 for Hypothyroidism with the course ongoing; Atorvastatin (Statin) administered via the Intramuscular route at a dosage of 98mg, initiated on 2024-07-04 for Hypercholesterolemia with the course ongoing.

On approximately 2024-08-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Dizziness. The Angioedema was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Account happen eight behavior break customer discover. Design theory today rise the.</data>
report_id: ADR-2024-472
report_date: '2024-09-08'
patient_details:
  patient_id: ANON-PX-7528
  gender: Female
  relevant_history:
  - coronary artery disease
  - asthma
  - type 2 diabetes
  age_at_reaction: 89
suspected_drugs:
- drug_name: Levothyroxine
  dosage: 46mg
  route_of_administration: Intramuscular
  start_date: '2024-07-04'
  indication_for_use: Hypothyroidism
  drug_class: Thyroid hormone
- drug_name: Atorvastatin
  dosage: 98mg
  route_of_administration: Intramuscular
  start_date: '2024-07-04'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
adverse_reactions:
- symptom_name: Angioedema
  onset_date: '2024-08-15'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: true
- symptom_name: Dizziness
  onset_date: '2024-08-15'
  severity: Mild
  outcome: Fatal
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
  naranjo_score: 5
reporting_facility: Marshall Inc Medical Center
reporter_type: Pharmacist
notes: Account happen eight behavior break customer discover. Design theory today
  rise the.
